<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/64BC5E73-972F-41E1-A12C-D97DC9BDFB93"><gtr:id>64BC5E73-972F-41E1-A12C-D97DC9BDFB93</gtr:id><gtr:name>MRC Clinical Sciences Centre</gtr:name><gtr:address><gtr:line1>Faculty of Medicine Imperial College</gtr:line1><gtr:line2>London Hammersmith Campus</gtr:line2><gtr:line3>Du Cane Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W12 0NN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B80FA015-FF48-471E-839C-CB0CD2B7E9AD"><gtr:id>B80FA015-FF48-471E-839C-CB0CD2B7E9AD</gtr:id><gtr:name>Imanova</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8524F630-A91D-4A6B-ABEE-87DD63B3194E"><gtr:id>8524F630-A91D-4A6B-ABEE-87DD63B3194E</gtr:id><gtr:firstName>Eric</gtr:firstName><gtr:surname>Aboagye</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U120081322"><gtr:id>77436006-0A4B-4216-A421-EE080FFAED46</gtr:id><gtr:title>Molecular Therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U120081322</gtr:grantReference><gtr:abstractText>The new generation of therapies including gene therapy and therapies that attack processes that drive cancer present tremendous challenges in their development. The Molecular Therapy Programme is researching on new enabling technologies involving PET imaging that will provide the opportunity to develop such therapies efficiently. To do this we are injecting radiotracers - compounds containing radioactive tags on them - to specifically image virus delivery, as well as biological activity within the tumours. Although cancer patients will be studied, the technologies being developed/validated, as well as the biological processes being imaged in within the programme are sufficiently generic to find utility in other clinical disciplines.</gtr:abstractText><gtr:technicalSummary>This programme has established a Molecular Therapy group to develop and validate PET imaging methodologies in pre-clinical disease models and humans. We are using cancer as disease model with which to assess the pharmacology of imaging agents. The initial focus is on the assessment of gene expression, and anti-proliferative activity of gene directed therapies, viral and non-viral. The human sodium iodide symporter reporter gene (hNIS) system together with Na[124I as well as bioluminescence methods are being explored to establish viral delivery. Furthermore, the biological activity of novel anti-cancer therapies are being examined for inhibition of proliferation in tumours (with [18F]fluorothymidine). Another area of interest is assessing mechanisms of action including induction of inflammation (with [11C]PK11195), pathway specific-imaging for mitogen activated protein kinase activity and angiogenesis. We aim to determine whether these radiotracers measure the biological processes for which they are intended to measure in an accurate, quantitative and reproducible manner. Although the studies will be done in cancer patients, the technologies should be widely applicable to other clinical areas of research; cancer offers a unique way of validating the radiotracers. The research outcomes will be published to enable use by scientists in academia and industry. The methods will play a major role in translation research programmes to develop new therapeutics and hence should have commercial and collaborative potential. We will iterate the pre-clinical and clinical programmes in a unique way to enhance the scientific value of the programme.</gtr:technicalSummary><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>5714828</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imanova</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Imanova</gtr:description><gtr:id>B4F8DFCD-4D56-4F92-A430-54ED1FB6D346</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>ZWuZZWpqMkn-1</gtr:outcomeId><gtr:partnerContribution>We have been able to use the very high level radiochemistry development labs.</gtr:partnerContribution><gtr:piContribution>We have provided personnel to allow the transition of tracers we have developed into First in Man studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>GE Healthcare Imanet</gtr:description><gtr:id>3C9AB116-181D-4BEC-98AF-83953B846BDC</gtr:id><gtr:impact>Publications: 19773436, 19706823, 19049429, 18794263, 18483090. Also two patents.</gtr:impact><gtr:outcomeId>A13A86CDB2F-1</gtr:outcomeId><gtr:partnerContribution>Practical and intellectual input, plus access to specialist facilities.</gtr:partnerContribution><gtr:piContribution>Practical and intellectual input, faciliteis and equipment plus staff.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BRC Public Discussion</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C5FCBF2F-A78F-4DD6-B672-F678A3E7B898</gtr:id><gtr:impact>Local Health Professinoals and members of the public who are interested in the research here at Hammersmith Hospital as funded via the BRC initiative attended an afternoon of presentations where they could become better informed about the research and discuss this with the BRC Theme Leads.

Local Healthcare Professionals and patients are more aware of the research being undertaken at Hammersmith.</gtr:impact><gtr:outcomeId>eazu6sLJrNQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Race-for-life' London, UK, 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FA508F77-8043-4866-8475-DD7F7B497E8E</gtr:id><gtr:impact>Members of the public were made more ware of the scientific research being undertaken in Cancer.

Nothing quantifiable to date.</gtr:impact><gtr:outcomeId>MUXJaowYG5S</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Summer student</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1513B3D7-9717-4BF5-88C3-D23C589DB91B</gtr:id><gtr:impact>An 'A' level school student was given hands-on experience of working in a laboratory research setting for 1 week during the school holidays.

A potential future scientific researcher was engaged with science more closely than usually possible.</gtr:impact><gtr:outcomeId>30165AD8832</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nuffield Bursary Students</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0BD3BE3E-BAA4-4595-B62D-1DD04AABA517</gtr:id><gtr:impact>4 students worked in the laboratory on a project for between 2 and 6 weeks.

Students were awarded a British Science Association Gold Crest Award for their individual projects that they submitted on teh work they had undertaken in the lab.</gtr:impact><gtr:outcomeId>RKgHM4edMwg</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'A' Level Careers Visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A3D5B143-4C06-4C99-B9D0-1728F84CFAC0</gtr:id><gtr:impact>6 students from the region visited to talk to researchers in the lab regarding future career choices and aspirations. Students were given a visit to the lab and researcher told them of their experiences at University to help the students decide if this was the right choice for them.

We now have close links to a number of schools in the region and will be hosting future visits to encourge participation in science.</gtr:impact><gtr:outcomeId>tFaYusRABPo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Undergraduate summer student</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>92E3CC7B-B1F7-48D2-93FC-953BCF24AC65</gtr:id><gtr:impact>An undergraduate student from Brunel University reqested to spend time working in the lab to experience hands-on the workings of a research laboratory.

A potential future scientific researcher was engaged with science more closely than usually possible.</gtr:impact><gtr:outcomeId>6A9403EF5EC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Summer A Level student</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3AE3700D-3DFF-4FC5-8617-5D218A1B9E94</gtr:id><gtr:impact>Participant in Post-16 Nuffield Foundation Summer Studentships Programme - an 'A' Level student was given hands-on experience of working in a laboratory research setting for 4 weeks during the school holidays.
Repeated annually

A potential future scientific researcher was engaged with science more closely than usually possible.</gtr:impact><gtr:outcomeId>4F5EC0285B2</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2011,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A Level Student work Experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>984717E3-4635-4B49-ABB1-8628972CBCF4</gtr:id><gtr:impact>Three A Level students were hosted on week work experience visits.

The A Level students were able to appreciate the potential of studying science at University and going into a scientific career.</gtr:impact><gtr:outcomeId>tTZteLNU3V2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK Donor Visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4411FFEE-39B7-40C9-9835-46AC94AE8A5F</gtr:id><gtr:impact>Tour and explanation of research work and facilites given to donor to CRUK

None to date</gtr:impact><gtr:outcomeId>0E2CFC7953A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Cancer Research Institute PET Research Steering committee (UK)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>731A213B-E69D-4A36-AF4B-0DE0758B760A</gtr:id><gtr:outcomeId>045DDA69EE8</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>French National Cancer Institute</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>6F81E30C-07C2-4BF8-A738-3B216B8DBD89</gtr:id><gtr:outcomeId>FBF4A1DA775</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Cancer Institute, Quantitative Imaging Study Section (USA)</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>A3864F8E-215B-434B-83AB-4F6BB0A0A66F</gtr:id><gtr:outcomeId>3674F28E97C</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cancer Research UK New Agents Committee (UK)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4D9B8DAF-4053-4422-A40F-EC6C52889419</gtr:id><gtr:outcomeId>0620056B982</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Cancer Research Institute Translational Clinical Studies Group (UK)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DE6F2507-DFF1-4C81-BEAA-7C506021F821</gtr:id><gtr:outcomeId>33B44A6318B</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Teaching</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>99C9342D-67BD-46BF-B757-C0053784A3E7</gtr:id><gtr:outcomeId>027CC34F212</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Multi-disciplinary Advisory Committee on Non-Invasive Imaging Studies (USA)</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>49D7D21F-7180-4837-A6A0-0C440E476B1C</gtr:id><gtr:outcomeId>1C54975B578</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Difficulties in direct measurement of drug concentrations in human tissues have hampered the understanding of drug accumulation in tumors and normal tissues. We propose a new system analysis modeling approach to characterize drug distribution in tissues based on human positron emission tomography (PET) data. The PET system analysis method was applied to temozolomide, an important alkylating agent used in the treatment of brain tumors, as part of standard temozolomide treatment regimens in patients. The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m2/d).</gtr:description><gtr:id>A3E9720D-9BB6-4400-AF56-8CDD5CAEBE91</gtr:id><gtr:impact>The method is considered a robust tool to analyze and predict tissue drug concentrations to help select the most rational dosing schedules.</gtr:impact><gtr:outcomeId>970DFFE7B67</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>New model for prediction of drug distribution - temozolomide</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Data sets from scanned subject cohorts</gtr:description><gtr:id>7073E334-16BB-49A6-BFAC-618223B90394</gtr:id><gtr:impact>Material allowing improved modelling techniques to be developed for analysis.</gtr:impact><gtr:outcomeId>35B6C4CBE88</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Scan data sets</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New temporal intensity information based voxel clustering approach - kinetic spatial filter (KSF) - that reduces the signal from the normal liver whilst retaining signal from tumours</gtr:description><gtr:id>77EECD34-CDDB-4EF7-9084-10FB4AED64F3</gtr:id><gtr:impact>We have published this technique having created it using scan data collected from MRC historical and currently funded work. This has been published (PMID: 20071760) and is now being implimented on new trials to provide proof of viability as a clinical tool.</gtr:impact><gtr:outcomeId>P2jshq6yED9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Kinetic Spatial Filter</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20071760</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B027C928-FCAC-4EBD-8000-0C70098D4172</gtr:id><gtr:title>Positron emission tomographic imaging of CXCR4 in cancer: challenges and promises.</gtr:title><gtr:parentPublicationTitle>Molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3370b4c7528068f12daef189be7eb65"><gtr:id>d3370b4c7528068f12daef189be7eb65</gtr:id><gtr:otherNames>George GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-3508</gtr:issn><gtr:outcomeId>5460b04c9ead09.55655859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B920B946-FE3F-46C2-AA5E-EEA6C0A31D49</gtr:id><gtr:title>Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3&amp;acute;-deoxy-3&amp;acute;-fluorothymidine PET: a pilot study.</gtr:title><gtr:parentPublicationTitle>Biomarkers in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f69b3fcc06a84265962e5f8711a85a6"><gtr:id>7f69b3fcc06a84265962e5f8711a85a6</gtr:id><gtr:otherNames>Contractor K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1752-0363</gtr:issn><gtr:outcomeId>pm_15233_23_22448798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>488B1A4B-F240-44BF-853C-0A6AC87993F7</gtr:id><gtr:title>The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68c6ccc5223584d4bf8bbb9bb54c5c7f"><gtr:id>68c6ccc5223584d4bf8bbb9bb54c5c7f</gtr:id><gtr:otherNames>Barthel H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>34A25F3274A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0C778A9-078A-46D2-8695-52E66A609698</gtr:id><gtr:title>Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a22197de98539caca8bee2009a88c9f"><gtr:id>7a22197de98539caca8bee2009a88c9f</gtr:id><gtr:otherNames>Gray KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>d7tbqVmub6V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>195E6B8B-AA18-4AC4-BBFF-D755E2098250</gtr:id><gtr:title>A multifractal approach to space-filling recovery for PET quantification.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ea4ab46b8b2c2fbe4982c3c95073702"><gtr:id>4ea4ab46b8b2c2fbe4982c3c95073702</gtr:id><gtr:otherNames>Willaime JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>5460b04d1faa87.12304840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B347C7B1-BFAC-4716-8EBA-365B2730F297</gtr:id><gtr:title>Parametric imaging of &amp;sup1;8F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9af2668d77c8ecdf7e5ae1c6b30b68b5"><gtr:id>9af2668d77c8ecdf7e5ae1c6b30b68b5</gtr:id><gtr:otherNames>Veronese M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>5412fe0bdff803.47777416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6686E4E5-9EAD-4ECB-B1EE-8962158F7405</gtr:id><gtr:title>Introduction to the analysis of PET data in oncology.</gtr:title><gtr:parentPublicationTitle>Journal of pharmacokinetics and pharmacodynamics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49d1ebc4c13ad82ac9c46d6d8f88adf6"><gtr:id>49d1ebc4c13ad82ac9c46d6d8f88adf6</gtr:id><gtr:otherNames>Tomasi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1567-567X</gtr:issn><gtr:outcomeId>pm_15233_23_23443280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAD4CAA9-637D-4CC8-B6DB-0E0190BAA84A</gtr:id><gtr:title>The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f14f5efac590a3e3059dd6822b19286"><gtr:id>4f14f5efac590a3e3059dd6822b19286</gtr:id><gtr:otherNames>McParland BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>C5250BC3CEB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80FD822A-DB8B-462E-9685-F4231B98551F</gtr:id><gtr:title>Automated GMP synthesis of [(18)F]ICMT-11 for in vivo imaging of caspase-3 activity.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd5d01fff162095281bef00c9263eeb7"><gtr:id>fd5d01fff162095281bef00c9263eeb7</gtr:id><gtr:otherNames>Fortt R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-8051</gtr:issn><gtr:outcomeId>pm_15233_23_22575271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D30AEE12-29A6-4207-9F3E-2678E18509D0</gtr:id><gtr:title>Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc0a46757930e0dccee6fb2e64e73f6b"><gtr:id>dc0a46757930e0dccee6fb2e64e73f6b</gtr:id><gtr:otherNames>Yau K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>3403A17FA78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27849473-2935-4D35-924F-89DF18683DBF</gtr:id><gtr:title>[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42982e0630ff71f3712f87a3ebdee802"><gtr:id>42982e0630ff71f3712f87a3ebdee802</gtr:id><gtr:otherNames>Contractor KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>DVpK3xSLC6Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DB1A3B3-4D6A-4CE8-979B-D122250071EF</gtr:id><gtr:title>Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ea4ab46b8b2c2fbe4982c3c95073702"><gtr:id>4ea4ab46b8b2c2fbe4982c3c95073702</gtr:id><gtr:otherNames>Willaime JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>pm_15233_23_23257054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A48D85E3-4804-4665-82ED-294DE14BCA58</gtr:id><gtr:title>Comparative assessment of segmentation algorithms for tumor delineation on a test-retest [(11)C]choline dataset.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49d1ebc4c13ad82ac9c46d6d8f88adf6"><gtr:id>49d1ebc4c13ad82ac9c46d6d8f88adf6</gtr:id><gtr:otherNames>Tomasi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>pm_15233_23_23231305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>932F7311-EE92-46A6-B4DE-D8A911B849FB</gtr:id><gtr:title>Comparison between diffusion-weighted MRI (DW-MRI) at 1.5 and 3 tesla: a phantom study.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba93c5a807719185be1e0c4998d32095"><gtr:id>ba93c5a807719185be1e0c4998d32095</gtr:id><gtr:otherNames>Lavdas I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>5412fe0d16c384.38801453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>158FFB40-A767-465B-AA71-D21A0BD19034</gtr:id><gtr:title>The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e619db95c406daaa114b6b1fa2b748f9"><gtr:id>e619db95c406daaa114b6b1fa2b748f9</gtr:id><gtr:otherNames>Pardo OE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_15233_13_19903855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A18E3CAC-3E3B-48FF-8945-94A8B404EE9F</gtr:id><gtr:title>Quantification of receptor-ligand binding with [&amp;sup1;8F]fluciclatide in metastatic breast cancer patients.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49d1ebc4c13ad82ac9c46d6d8f88adf6"><gtr:id>49d1ebc4c13ad82ac9c46d6d8f88adf6</gtr:id><gtr:otherNames>Tomasi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>pm_53cd4ddd4dde263ea</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11A34329-07FD-4120-B82F-252C2A2E7D31</gtr:id><gtr:title>Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef57da05671d01a0569e27329ec78e96"><gtr:id>ef57da05671d01a0569e27329ec78e96</gtr:id><gtr:otherNames>Kenny LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>RSwoTv3joKX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>745B6E63-1D53-432B-B0DE-D18C86FD294D</gtr:id><gtr:title>Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49d1ebc4c13ad82ac9c46d6d8f88adf6"><gtr:id>49d1ebc4c13ad82ac9c46d6d8f88adf6</gtr:id><gtr:otherNames>Tomasi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>pm_15233_23_22421332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F17C7601-EB30-498F-B84A-C411CC3FCFA2</gtr:id><gtr:title>Radiolabeled RGD tracer kinetics annotates differential av? 3 integrin expression linked to cell intrinsic and vessel expression.</gtr:title><gtr:parentPublicationTitle>Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b13f95cf7a3c55dd20bb63682e25ff9"><gtr:id>0b13f95cf7a3c55dd20bb63682e25ff9</gtr:id><gtr:otherNames>Alam IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1536-1632</gtr:issn><gtr:outcomeId>5412cb2f284575.27171720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F149310-43F1-4839-8F4B-C9FD8A8F3694</gtr:id><gtr:title>A novel radiotracer to image glycogen metabolism in tumors by positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6747859800260f7998989a4d593d5fb7"><gtr:id>6747859800260f7998989a4d593d5fb7</gtr:id><gtr:otherNames>Witney TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5412fe0b4440a9.02911451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D450FDD-FF36-4766-A411-4F96BAB5E3DE</gtr:id><gtr:title>Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef57da05671d01a0569e27329ec78e96"><gtr:id>ef57da05671d01a0569e27329ec78e96</gtr:id><gtr:otherNames>Kenny LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>20794887585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E866839-5043-4688-80BD-CC470EB08073</gtr:id><gtr:title>Monitoring predominantly cytostatic treatment response with 18F-FDG PET.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42982e0630ff71f3712f87a3ebdee802"><gtr:id>42982e0630ff71f3712f87a3ebdee802</gtr:id><gtr:otherNames>Contractor KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>87852D5F113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88ADD936-7B06-4CFF-99B6-48D9DCF1B944</gtr:id><gtr:title>Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef57da05671d01a0569e27329ec78e96"><gtr:id>ef57da05671d01a0569e27329ec78e96</gtr:id><gtr:otherNames>Kenny LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>E2B2F064D8B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35D8F7F7-F47B-476C-990A-BDA4AA706ABF</gtr:id><gtr:title>Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44222c78ec454beafd9c72ad49d6c46e"><gtr:id>44222c78ec454beafd9c72ad49d6c46e</gtr:id><gtr:otherNames>Chan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>5C8CC1D8D3B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4473EA8D-6602-4751-B32F-ADEBC74F0091</gtr:id><gtr:title>Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/136b4cee61c255d874b84a19e251c095"><gtr:id>136b4cee61c255d874b84a19e251c095</gtr:id><gtr:otherNames>Nguyen QD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_15233_23_23729364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>580B805E-D529-4F65-A877-33D1BAD8A95A</gtr:id><gtr:title>PET imaging with multimodal upconversion nanoparticles.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14884f7d0f24eafea4348dc8d90f14a5"><gtr:id>14884f7d0f24eafea4348dc8d90f14a5</gtr:id><gtr:otherNames>Gallo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>5412fe0aca0f18.03122173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67E26D8F-FC81-4934-80C8-40F26504D599</gtr:id><gtr:title>Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d632792a68822ae75e4563d1222704e"><gtr:id>5d632792a68822ae75e4563d1222704e</gtr:id><gtr:otherNames>Leyton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>7B6ECD0B6C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>537BB563-0A87-4F09-95AA-92B4A3822653</gtr:id><gtr:title>Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dccf94f66a80289f9a4c640ae5644682"><gtr:id>dccf94f66a80289f9a4c640ae5644682</gtr:id><gtr:otherNames>Pillai RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>189A738730E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>779DC96E-7432-4B90-8674-D91A60E94D63</gtr:id><gtr:title>Radiosynthesis and pre-clinical evaluation of [(18)F]fluoro-[1,2-(2)H(4)]choline.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/adac6518578f2021c5823016d77e9f57"><gtr:id>adac6518578f2021c5823016d77e9f57</gtr:id><gtr:otherNames>Smith G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-8051</gtr:issn><gtr:outcomeId>541300f77cec83.02110577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B8D5E4B-8A26-4D7B-AAA0-C8571CBBABCE</gtr:id><gtr:title>Imaging the life and death of tumors in living subjects: Preclinical PET imaging of proliferation and apoptosis.</gtr:title><gtr:parentPublicationTitle>Integrative biology : quantitative biosciences from nano to macro</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/136b4cee61c255d874b84a19e251c095"><gtr:id>136b4cee61c255d874b84a19e251c095</gtr:id><gtr:otherNames>Nguyen QD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1757-9694</gtr:issn><gtr:outcomeId>pm_15233_23_20737104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B62D9CD6-11F1-4543-84C0-44605F65600D</gtr:id><gtr:title>Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8daaabf2c4782bef479bb7d8bf61ec29"><gtr:id>8daaabf2c4782bef479bb7d8bf61ec29</gtr:id><gtr:otherNames>Gupta N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>62A5920D23F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F383D3A6-E6AF-402B-B802-32201E47C982</gtr:id><gtr:title>[(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9f6cc98ad514edb63fcf4f57092d90e"><gtr:id>b9f6cc98ad514edb63fcf4f57092d90e</gtr:id><gtr:otherNames>Soloviev D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>pm_15233_23_22209266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FC50411-A637-45BA-B34C-703FCC2392C9</gtr:id><gtr:title>A phantom for diffusion-weighted MRI (DW-MRI).</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba93c5a807719185be1e0c4998d32095"><gtr:id>ba93c5a807719185be1e0c4998d32095</gtr:id><gtr:otherNames>Lavdas I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>pm_15233_23_23576443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC93C2B2-4189-4A3C-8AF5-FDD49076D6B8</gtr:id><gtr:title>In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d632792a68822ae75e4563d1222704e"><gtr:id>5d632792a68822ae75e4563d1222704e</gtr:id><gtr:otherNames>Leyton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>439FF02C28F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C29F555-0F6F-4656-889B-C4617463B431</gtr:id><gtr:title>Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15a5504954e7abd4ba416a3c61ecfa02"><gtr:id>15a5504954e7abd4ba416a3c61ecfa02</gtr:id><gtr:otherNames>Tennant DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>0ED2A4047CE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC83E627-50CC-489C-ABEF-F5CD58D4DED7</gtr:id><gtr:title>[18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d632792a68822ae75e4563d1222704e"><gtr:id>5d632792a68822ae75e4563d1222704e</gtr:id><gtr:otherNames>Leyton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>B468720B630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>147D416A-B47C-426E-B465-0042B7244C8E</gtr:id><gtr:title>Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/136b4cee61c255d874b84a19e251c095"><gtr:id>136b4cee61c255d874b84a19e251c095</gtr:id><gtr:otherNames>Nguyen QD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>9589C98F6CC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F28EBFC-F367-4612-9ACB-CB4683295403</gtr:id><gtr:title>Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f69b3fcc06a84265962e5f8711a85a6"><gtr:id>7f69b3fcc06a84265962e5f8711a85a6</gtr:id><gtr:otherNames>Contractor K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_53cd4ddd4ddbed59b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>424266C2-2C65-45AB-B274-F8EC1A03A6B3</gtr:id><gtr:title>Biological basis of [&amp;sup1;&amp;sup1;C]choline-positron emission tomography in patients with breast cancer: comparison with [&amp;sup1;8F]fluorothymidine positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42982e0630ff71f3712f87a3ebdee802"><gtr:id>42982e0630ff71f3712f87a3ebdee802</gtr:id><gtr:otherNames>Contractor KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0143-3636</gtr:issn><gtr:outcomeId>pCJ6gLbP6DD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7986F777-3BD3-433E-B5A8-4DC632371B76</gtr:id><gtr:title>Glucose metabolism measured by [&amp;sup1;8F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells.</gtr:title><gtr:parentPublicationTitle>Translational oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/136b4cee61c255d874b84a19e251c095"><gtr:id>136b4cee61c255d874b84a19e251c095</gtr:id><gtr:otherNames>Nguyen QD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1936-5233</gtr:issn><gtr:outcomeId>pm_15233_23_21804920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACE467DE-6EA0-455D-9578-45270CB1377D</gtr:id><gtr:title>A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cbb6f59ad7b88bb49fa1b2738499d74"><gtr:id>3cbb6f59ad7b88bb49fa1b2738499d74</gtr:id><gtr:otherNames>Kaliszczak M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_15233_23_23322205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>243ED26E-523E-4BEC-A3F7-A7E9A93FF6D3</gtr:id><gtr:title>Imaging in drug development.</gtr:title><gtr:parentPublicationTitle>Clinical advances in hematology &amp; oncology : H&amp;O</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/745a56d9aa5de2df71282fed3b9118e4"><gtr:id>745a56d9aa5de2df71282fed3b9118e4</gtr:id><gtr:otherNames>Aboagye EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1543-0790</gtr:issn><gtr:outcomeId>pm_15233_13_17235274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00C76171-F523-4045-8000-CB441BEA305B</gtr:id><gtr:title>A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ebb3b9565e6b270321a69df0b791e19"><gtr:id>8ebb3b9565e6b270321a69df0b791e19</gtr:id><gtr:otherNames>Rosso L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>91EFCEBC330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>869C3BBF-A586-4B8D-BBE9-8C68ABD69EE5</gtr:id><gtr:title>Clinical translation of molecular imaging agents used in PET studies of cancer.</gtr:title><gtr:parentPublicationTitle>Advances in cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef57da05671d01a0569e27329ec78e96"><gtr:id>ef57da05671d01a0569e27329ec78e96</gtr:id><gtr:otherNames>Kenny LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9780124116382</gtr:isbn><gtr:issn>0065-230X</gtr:issn><gtr:outcomeId>5460d8687caf11.64144792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>496961F8-34F0-42C7-A601-F5CC71F549FF</gtr:id><gtr:title>Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef57da05671d01a0569e27329ec78e96"><gtr:id>ef57da05671d01a0569e27329ec78e96</gtr:id><gtr:otherNames>Kenny LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>9472C711835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F10A087F-26E7-47D6-B012-A07BF06686C2</gtr:id><gtr:title>Positron emission tomography imaging of small animals in anticancer drug development.</gtr:title><gtr:parentPublicationTitle>Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/745a56d9aa5de2df71282fed3b9118e4"><gtr:id>745a56d9aa5de2df71282fed3b9118e4</gtr:id><gtr:otherNames>Aboagye EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1536-1632</gtr:issn><gtr:outcomeId>pm_15233_13_15912276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8588EAD0-9A15-4860-98B9-528CF1826FA5</gtr:id><gtr:title>Synthesis and evaluation of nucleoside radiotracers for imaging proliferation.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/adac6518578f2021c5823016d77e9f57"><gtr:id>adac6518578f2021c5823016d77e9f57</gtr:id><gtr:otherNames>Smith G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-8051</gtr:issn><gtr:outcomeId>pm_15233_23_22321533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70550444-5B47-4BAB-8B29-CFDB4C3B478B</gtr:id><gtr:title>Novel PET biomarkers for breast cancer imaging.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef57da05671d01a0569e27329ec78e96"><gtr:id>ef57da05671d01a0569e27329ec78e96</gtr:id><gtr:otherNames>Kenny LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0143-3636</gtr:issn><gtr:outcomeId>541300f74e5945.32708217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EA955AC-1A89-4373-B8B1-8522656FECFC</gtr:id><gtr:title>Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6747859800260f7998989a4d593d5fb7"><gtr:id>6747859800260f7998989a4d593d5fb7</gtr:id><gtr:otherNames>Witney TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_15233_23_22235095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED86AB9C-7683-4F35-8C3F-AD683149935C</gtr:id><gtr:title>Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56f74194f522e23a453e4fda641c2653"><gtr:id>56f74194f522e23a453e4fda641c2653</gtr:id><gtr:otherNames>Hatt M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>doi_53cd4dd4dd525416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5408603-5676-4294-A857-970185FC5AFF</gtr:id><gtr:title>Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9169562820df35675f4cd5ca3a865be7"><gtr:id>9169562820df35675f4cd5ca3a865be7</gtr:id><gtr:otherNames>Buluwela L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>95BF400114B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4707446-AE95-4950-B819-AA108D1D07C1</gtr:id><gtr:title>Evaluation of limited blood sampling population input approaches for kinetic quantification of [18F]fluorothymidine PET data.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42982e0630ff71f3712f87a3ebdee802"><gtr:id>42982e0630ff71f3712f87a3ebdee802</gtr:id><gtr:otherNames>Contractor KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_15233_23_22444834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D897D722-B7C3-4B7F-A593-1C036210660B</gtr:id><gtr:title>Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b4686cf43b91f9d763ab464922841c6"><gtr:id>8b4686cf43b91f9d763ab464922841c6</gtr:id><gtr:otherNames>Saleem A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>099CC57F116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B1D76C1-3D4A-426C-BD42-0717C75DF6E5</gtr:id><gtr:title>Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/adac6518578f2021c5823016d77e9f57"><gtr:id>adac6518578f2021c5823016d77e9f57</gtr:id><gtr:otherNames>Smith G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>4FD16A1E47A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C052F123-66DA-4B3D-9710-9400431ED318</gtr:id><gtr:title>Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acfc3fc3032aa1ca2c1d9e812cb8be4c"><gtr:id>acfc3fc3032aa1ca2c1d9e812cb8be4c</gtr:id><gtr:otherNames>Workman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>pm_15233_13_16670384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9F14E51-0182-4FDD-89EE-81527C05E92E</gtr:id><gtr:title>Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c517f20f604c93911282f1a8e3fb6e"><gtr:id>85c517f20f604c93911282f1a8e3fb6e</gtr:id><gtr:otherNames>Perumal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>A2DAC0CD5F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F479FA22-6FB8-4CA3-BA06-5DE3D6F32EA0</gtr:id><gtr:title>Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4ff435017ba588fb2b3e0b19168781"><gtr:id>cb4ff435017ba588fb2b3e0b19168781</gtr:id><gtr:otherNames>Zhao L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_15233_23_23900048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2A644EC-B1AE-4750-A05B-6A2ADE58D72F</gtr:id><gtr:title>Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f69b3fcc06a84265962e5f8711a85a6"><gtr:id>7f69b3fcc06a84265962e5f8711a85a6</gtr:id><gtr:otherNames>Contractor K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>pm_15233_23_22572708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A6174ED-21E8-456E-9E7E-8F4E6AF2A9B9</gtr:id><gtr:title>Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/136b4cee61c255d874b84a19e251c095"><gtr:id>136b4cee61c255d874b84a19e251c095</gtr:id><gtr:otherNames>Nguyen QD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>pm_15233_23_22226480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D89CF59-AE4B-45F9-9D54-A5DEDBE9E7B6</gtr:id><gtr:title>[11C]choline positron emission tomography in estrogen receptor-positive breast cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42982e0630ff71f3712f87a3ebdee802"><gtr:id>42982e0630ff71f3712f87a3ebdee802</gtr:id><gtr:otherNames>Contractor KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>8A852EA231D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC44F1A4-5FCA-41CF-9DF6-2CF7FF089F11</gtr:id><gtr:title>Bioorthogonal chemistry for (68) Ga radiolabelling of DOTA-containing compounds.</gtr:title><gtr:parentPublicationTitle>Journal of labelled compounds &amp; radiopharmaceuticals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ae448b0d55f4d694c4a1a62b22106c0"><gtr:id>0ae448b0d55f4d694c4a1a62b22106c0</gtr:id><gtr:otherNames>Evans HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>5412cb2e9c28f0.92258245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B48837D-72FC-4942-84C2-1E3BC10B98A3</gtr:id><gtr:title>Radiosynthesis and in vivo tumor uptake of 2-deoxy-2-[(18)F]fluoro-myo-inositol.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260c018c7e34a0fea0030347894c4c2d"><gtr:id>260c018c7e34a0fea0030347894c4c2d</gtr:id><gtr:otherNames>Carroll L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_15233_23_22944120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51865496-790C-48AF-A5D9-DC84BFD7F207</gtr:id><gtr:title>Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc3036c496fae6d14be446544d46c018"><gtr:id>bc3036c496fae6d14be446544d46c018</gtr:id><gtr:otherNames>Kenny L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>227BD290B27</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAF4B8E1-4D42-47CF-AFEB-F7E8EE353F1C</gtr:id><gtr:title>Preclinical evaluation of a CXCR4-specific (68)Ga-labelled TN14003 derivative for cancer PET imaging.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3370b4c7528068f12daef189be7eb65"><gtr:id>d3370b4c7528068f12daef189be7eb65</gtr:id><gtr:otherNames>George GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>5412fe09235d74.46463676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73A7AB1D-5BE1-4D11-BC97-A2D40F822D64</gtr:id><gtr:title>Synthesis of a new fluorine-18 glycosylated 'click' cyanoquinoline for the imaging of epidermal growth factor receptor.</gtr:title><gtr:parentPublicationTitle>Journal of labelled compounds &amp; radiopharmaceuticals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab4efafe9075b478cde7643fc166371d"><gtr:id>ab4efafe9075b478cde7643fc166371d</gtr:id><gtr:otherNames>Pisaneschi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0362-4803</gtr:issn><gtr:outcomeId>5412cb2edd0614.97072673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>131BD0FC-ABCE-40E4-AA07-E8C95461FDF0</gtr:id><gtr:title>Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents.</gtr:title><gtr:parentPublicationTitle>American journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72cae8014de91ea48867bbe3bd705235"><gtr:id>72cae8014de91ea48867bbe3bd705235</gtr:id><gtr:otherNames>Tietz O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15233_23_23901361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>754B244B-F6E6-4A6C-A547-174F2C2B9F6D</gtr:id><gtr:title>Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d632792a68822ae75e4563d1222704e"><gtr:id>5d632792a68822ae75e4563d1222704e</gtr:id><gtr:otherNames>Leyton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>F1E2B343058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7F959F7-CE6C-4A59-A24A-9BE5A6458AB4</gtr:id><gtr:title>Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e45c17f8bfdd73e9467b7e748eea2625"><gtr:id>e45c17f8bfdd73e9467b7e748eea2625</gtr:id><gtr:otherNames>Filipovic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>5460b04c506f13.93329396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>305118E1-4B12-4430-BF64-A62713721047</gtr:id><gtr:title>CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14884f7d0f24eafea4348dc8d90f14a5"><gtr:id>14884f7d0f24eafea4348dc8d90f14a5</gtr:id><gtr:otherNames>Gallo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>5412fe0df32ef9.66458238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5B2DE43-E12C-46DF-8411-C5A523E9094D</gtr:id><gtr:title>Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78f0d2c983d64542eca4aba75d3c085"><gtr:id>c78f0d2c983d64542eca4aba75d3c085</gtr:id><gtr:otherNames>Challapalli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0143-3636</gtr:issn><gtr:outcomeId>5412cb2e184687.07047964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8F43BBC-B520-46E1-BCBB-E8F95452008D</gtr:id><gtr:title>Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab4efafe9075b478cde7643fc166371d"><gtr:id>ab4efafe9075b478cde7643fc166371d</gtr:id><gtr:otherNames>Pisaneschi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>pm_15233_23_20797871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>973F0D64-6D1B-4EEC-AEEE-C604F69304AC</gtr:id><gtr:title>Development of radiotracers for oncology--the interface with pharmacology.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f01aee55e92ee99444433dc058e18197"><gtr:id>f01aee55e92ee99444433dc058e18197</gtr:id><gtr:otherNames>Sharma R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>541300f7aff0c6.21825895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6031AFC0-0237-4E14-BC1F-B523CF748B00</gtr:id><gtr:title>The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/745a56d9aa5de2df71282fed3b9118e4"><gtr:id>745a56d9aa5de2df71282fed3b9118e4</gtr:id><gtr:otherNames>Aboagye EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>pm_15233_23_20716650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05F6242E-A6B1-403C-B47A-35FFEEE5EAAA</gtr:id><gtr:title>An in vivo multimodal imaging study using MRI and PET of stem cell transplantation after myocardial infarction in rats.</gtr:title><gtr:parentPublicationTitle>Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be898455a5464ddabc994302c8296c2"><gtr:id>3be898455a5464ddabc994302c8296c2</gtr:id><gtr:otherNames>Chapon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1536-1632</gtr:issn><gtr:outcomeId>0BEE2CBE93F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E3B5C60-22AE-4479-A2C7-6D6B8B2A7F4A</gtr:id><gtr:title>Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.</gtr:title><gtr:parentPublicationTitle>Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49d1ebc4c13ad82ac9c46d6d8f88adf6"><gtr:id>49d1ebc4c13ad82ac9c46d6d8f88adf6</gtr:id><gtr:otherNames>Tomasi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1536-1632</gtr:issn><gtr:outcomeId>gzMe9dVrPsq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75441DFF-958A-4FD9-88A9-F92FF237FEE5</gtr:id><gtr:title>Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78f0d2c983d64542eca4aba75d3c085"><gtr:id>c78f0d2c983d64542eca4aba75d3c085</gtr:id><gtr:otherNames>Challapalli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>5412fe09618df3.79324417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1DF40E2-1790-49A2-B301-0F2BE4CE8702</gtr:id><gtr:title>Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d632792a68822ae75e4563d1222704e"><gtr:id>5d632792a68822ae75e4563d1222704e</gtr:id><gtr:otherNames>Leyton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>BBABA31622A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1241099E-E205-4F49-869E-3B18EA8B1B59</gtr:id><gtr:title>Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cbb6f59ad7b88bb49fa1b2738499d74"><gtr:id>3cbb6f59ad7b88bb49fa1b2738499d74</gtr:id><gtr:otherNames>Kaliszczak M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_15233_23_24071597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>943AC806-7A8E-4582-87BD-3CEFE5F6BB5A</gtr:id><gtr:title>18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c78f0d2c983d64542eca4aba75d3c085"><gtr:id>c78f0d2c983d64542eca4aba75d3c085</gtr:id><gtr:otherNames>Challapalli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>pm_15233_23_23949910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE8FB8CA-5C5B-4DD4-8CF4-0653DFA8EA93</gtr:id><gtr:title>Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.</gtr:title><gtr:parentPublicationTitle>Drug metabolism and disposition: the biological fate of chemicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79c7adb54a9d13ed9c6d7b9bf16dd2a4"><gtr:id>79c7adb54a9d13ed9c6d7b9bf16dd2a4</gtr:id><gtr:otherNames>Sanderson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0090-9556</gtr:issn><gtr:outcomeId>8A3E86EA74C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4744BE22-D276-429E-A1EF-E2C9FADC55EA</gtr:id><gtr:title>Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85c517f20f604c93911282f1a8e3fb6e"><gtr:id>85c517f20f604c93911282f1a8e3fb6e</gtr:id><gtr:otherNames>Perumal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1536-1632</gtr:issn><gtr:outcomeId>pm_15233_23_22484552</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U120081322</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>